DelveInsight's "Oncolytic Adenovirus Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Oncolytic Adenovirus, historical and forecasted epidemiology as well as the Oncolytic Adenovirus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Oncolytic Adenovirus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Oncolytic Adenovirus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Oncolytic Adenovirus Market Forecast
Some of the key facts of the Oncolytic Adenovirus Market Report:
- The Oncolytic Adenovirus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In December 2024, TILT-123, an oncolytic adenovirus engineered with tumor necrosis factor alpha (TNFα) and interleukin-2 (IL-2), aims to improve the effectiveness of T-cell therapies such as immune checkpoint blockade and adoptive cell transfer. TILT's strategy leverages oncolytic viruses to selectively replicate within and destroy cancer cells while also boosting immune responses against the tumor.
- In April 2024, UK-based biotech firm Theolytics successfully raised £19 million ($24.5 million) in a funding round to support the advancement of its leading oncolytic adenovirus therapy, THEO-260.
- Expected launch of promising therapies shall fuel the growth of the market during the forecast period, i.e., 2022–2032
- Key Oncolytic Adenovirus Companies: CG Oncology, Inc., Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc., and others
- Key Oncolytic Adenovirus Therapies: CG0070, ORCA-010, OBP-301, DNX-2401, and others
Oncolytic Adenovirus Overview
Various forms of immunotherapy currently are emerging, including oncolytic viruses. In this therapy, viruses are engineered to selectively propagate in tumor cells and reduce toxicity for non-neoplastic tissues. Adenovirus is one of the most frequently employed oncolytic viruses because of its capacity in tumor cell lysis and immune response stimulation.
Oncolytic adenoviruses (OAds) are designed to replicate and induce oncolytic cell death selectively in tumor cells only by the deletion of a range of genes in the E1 region (55-kDagene in E1B, 24-bp gene in E1A, etc.) or driving the E1 gene expression through an integrated promoter (PSA, AFP, hTERT, etc.) that is activated in tumor cells.
Get a Free sample for the Oncolytic Adenovirus Market Report:
https://www.delveinsight.com/report-store/oncolytic-adenovirus-market
Oncolytic Adenovirus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Oncolytic Adenovirus Epidemiology Segmentation:
The Oncolytic Adenovirus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Oncolytic Adenovirus
- Prevalent Cases of Oncolytic Adenovirus by severity
- Gender-specific Prevalence of Oncolytic Adenovirus
- Diagnosed Cases of Episodic and Chronic Oncolytic Adenovirus
Download the report to understand which factors are driving Oncolytic Adenovirus epidemiology trends @ Oncolytic Adenovirus Epidemiological Insights
Oncolytic Adenovirus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Oncolytic Adenovirus market or expected to get launched during the study period. The analysis covers Oncolytic Adenovirus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Oncolytic Adenovirus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Oncolytic Adenovirus Therapies and Key Companies
- CG0070: CG Oncology, Inc.
- ORCA-010: Orca Therapeutics BV
- OBP-301: Syneos Health
- DNX-2401: DNAtrix, Inc.
To know more about Oncolytic Adenovirus treatment, visit @ Oncolytic Adenovirus Medications
Oncolytic Adenovirus Market Drivers
- Advances in Gene Therapy
- Rising Cancer Incidence
- FDA and Regulatory Support
- Combination Therapy Potential
- Growing Investments and Collaborations
- Personalized Medicine Approach
- Technological Advances in Viral Vector Production
Oncolytic Adenovirus Market Barriers
- High Development Costs
- Regulatory Challenges
- Limited Clinical Data
- Immune System Response
- Manufacturing Complexities
- Reimbursement and Pricing Issues
- Competition from Other Oncolytic Viruses
Scope of the Oncolytic Adenovirus Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Oncolytic Adenovirus Companies: CG Oncology, Inc., Orca Therapeutics BV, Syneos Health, DNAtrix, Inc., and others
- Key Oncolytic Adenovirus Therapies: CG0070, ORCA-010, OBP-301, DNX-2401, and others
- Oncolytic Adenovirus Therapeutic Assessment: Oncolytic Adenovirus current marketed and Oncolytic Adenovirus emerging therapies
- Oncolytic Adenovirus Market Dynamics: Oncolytic Adenovirus market drivers and Oncolytic Adenovirus market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Oncolytic Adenovirus Unmet Needs, KOL's views, Analyst's views, Oncolytic Adenovirus Market Access and Reimbursement
Discover more about therapies set to grab major Oncolytic Adenovirus market share @ Oncolytic Adenovirus Treatment Landscape
Table of Contents
- Oncolytic Adenovirus Market Report Introduction
- Executive Summary for Oncolytic Adenovirus
- SWOT analysis of Oncolytic Adenovirus
- Oncolytic Adenovirus Patient Share (%) Overview at a Glance
- Oncolytic Adenovirus Market Overview at a Glance
- Oncolytic Adenovirus Disease Background and Overview
- Oncolytic Adenovirus Epidemiology and Patient Population
- Country-Specific Patient Population of Oncolytic Adenovirus
- Oncolytic Adenovirus Current Treatment and Medical Practices
- Oncolytic Adenovirus Unmet Needs
- Oncolytic Adenovirus Emerging Therapies
- Oncolytic Adenovirus Market Outlook
- Country-Wise Oncolytic Adenovirus Market Analysis (2019-2032)
- Oncolytic Adenovirus Market Access and Reimbursement of Therapies
- Oncolytic Adenovirus Market Drivers
- Oncolytic Adenovirus Market Barriers
- Oncolytic Adenovirus Appendix
- Oncolytic Adenovirus Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Related Reports:
Oncolytic Adenovirus Pipeline
"Oncolytic Adenovirus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of current clinical development scenarios and growth prospects across the Oncolytic Adenovirus market. A detailed picture of the Oncolytic Adenovirus pipeline landscape is provided, which includes the disease overview and Oncolytic Adenovirus treatment guidelines.
Oncolytic Adenovirus Epidemiology
DelveInsight's 'Oncolytic Adenovirus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Oncolytic Adenovirus epidemiology in the 7MM, ie, the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website : https://www.delveinsight.com
